Your browser doesn't support javascript.
loading
Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1597-1604, 2017.
Article in Chinese | WPRIM | ID: wpr-301681
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and related factors of acquired deep molecular response(DMR) for treating patients with chronic myeloid leukemia(CML) by using TKI.</p><p><b>METHODS</b>The clinical data of 131 TKI-treated patients with CML were analyzed retrospectively. The therapeutic effects of each time-points were evaluated, and the related factors of MRwere analyzed.</p><p><b>RESULTS</b>The median follow up-time of 131 cases with CML was 24 months (6-120 months), among them the treatment of 30 patient was converted to nilotinib after a median of 12 months (1-69.6 months) with imatinib, and 13 patient was converted to dasatinib treatment after a median of 31.2 month (3.1-87.6 months) with imatinib. After treatment for 3, 6 and 12 month, the rate of major cytogenetic response (MCyR) was 78%, 79.4% and 95.9%, and the complete cytogenetic response (CCyR) rate was 48.8%, 66.7% and 73.5%, respectively. 60% patients obtained BCR-ABL<10% at 3 months, 56.3% patients obtained BCR-ABL<1% at 6 months, 55.2% patients obtained BCR-ABL<0.1% at 12 months. In continued imatinib therapy group, 53 patients (60.9%) obtained MR, and 33 cases (37.9%) obtained stable MR. Multivariate analysis showed that sex, WBC count at the time of diagnosis and BCR-ABLlevel at 3 months were independent factors for obtaining MR. The 3-month BCR-ABLlevel was an independent factor to obtain stable MR. 18 cases (40.9%) in the second-generation TKI group received MRand the 3-month BCR-ABLlevel was also an independent predictor for MR.</p><p><b>CONCLUSION</b>The excellent cytogenetic and molecular responses are observed in CML patients treated with cmatinib. Conversion to second-generation TKI therapy for patients with resistant or intolerant to imatinib also can achieve a satisfactory response and a higher rate of deeper molecular remission. The higher incidence of early molecular response predicting MRand stable MRis achieved.</p>
Full text: Available Index: WPRIM (Western Pacific) Type of study: Prognostic study Language: Chinese Journal: Journal of Experimental Hematology Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Prognostic study Language: Chinese Journal: Journal of Experimental Hematology Year: 2017 Type: Article